Expand The

Horizon

Each allogeneic hematopoietic stem cell transplant (allo-HSCT) is a personalized journey.

No paths are exactly alike,

but the outlook is the same:

hope on the horizon.

Join us on a new journey to extend the promise of allo-HSCT to more patients in need.

As cell therapy innovations redefine expectations of allo-hsct,
what new perspectives will lead us to:

Open the field

with more transplants for more waiting patients?

smooth the path

with optimized solutions and better outcomes?

clear the way

with a straightforward experience for patients?

Continue to find out more about today's landscape.

THE LANDSCAPE TODAY
THE LANDSCAPE TODAY

Over 18,000 new patients with hematologic malignancies are considered for allogeneic transplant each year, initiating their journey of hope.1

ALLO-HSCT OFFERS A CRITICAL ADVANTAGE to these patients by significantly improving survival rates when they proceed to transplant earlier in their treatment journey.2,3

ADVANCES IN THE LAST FEW DECADES HAVE SIGNIFICANTLY IMPROVED
ALLO-HSCT ACCESS AND OUTCOMES. SELECT TO FIND OUT MORE:

1970
Advent of unrelated
donor registries
1980
Introduction
of umbilical cord blood
(UCB) as a viable graft source
1990
Process of peripheral blood stem cell collection
Emergence
of reduced intensity conditioning regimens
2000
Increased sensitivity of chimerism analysis methods
2010
Improvement of post-transplant treatments for haploidentical recipients
2020
Development
of novel pharmaceutical agents as new treatment options
First established in 1974, this introduced a monumental shift that extended access to new donor sources for patients without access to a matched related donor.2

CONTINUE TO LEARN ABOUT CHALLENGES ALONG THE TRANSPLANT JOURNEY.

ADVANCES IN THE LAST FEW DECADES HAVE SIGNIFICANTLY IMPROVED
ALLO-HSCT ACCESS AND OUTCOMES. SELECT TO FIND OUT MORE:

1970

Advent of unrelated
donor registries

1980

Introduction
of umbilical cord blood
(UCB) as a viable graft source

1990

Process of peripheral blood stem cell collection
Emergence
of reduced intensity conditioning regimens

2000

Increased sensitivity of chimerism analysis methods

2010

Improvement of post-transplant treatments for haploidentical recipients

2020

Development
of novel pharmaceutical agents as new treatment options
First established in 1974, this introduced a monumental shift that extended access to new donor sources for patients without access to a matched related donor.2

CONTINUE TO LEARN ABOUT CHALLENGES ALONG THE TRANSPLANT JOURNEY.

A CHALLENGING JOURNEY
A CHALLENGING JOURNEY

Allogeneic transplant is a POTENTIALLY CURATIVE TREATMENT for patients with hematologic malignancies, but despite our achievements as a community, the transplant journey remains challenging.2

Every year, MORE THAN 10,000 PATIENTS who could benefit from allo-HSCT do not receive a transplant, and those who do experience anxiety and face challenges across the entire transplant journey.10,11

Navigate the patient journey to learn more about steps
and barriers along the way.

Patient Selection and Consideration for Transplant

Once referred to a transplanter, the determination of allo-HSCT eligibility and decision to proceed is complex, and reliant on clinical, non-clinical, and donor factors.11

Learn More About Clinical Barriers

Learn more about Non-Clinical Barriers

Donor sourcing and acquisition

The search for a donor source requires the full transplant team and may be unpredictable due to donor accessibility and the possibility of donor attrition. Selection of a donor source is ultimately at the discretion of the transplanter, and acquisition can range from 1 to 14+ months.12,13

Learn more about Donor-Related Barriers

Patient Preparation

Patients undergo myeloablative or reduced intensity conditioning before their infusion. In preparation for transplantation, and for the subsequent recovery period after undergoing allo-HSCT, patients need to secure a full-time caregiver and a strong support system.2,11

Transplantation

Day Zero represents the day of infusion of stem cells and also the beginning of the monitoring period, which requires careful planning and preparation by the transplant team, the patient, and their caregiver.2

Recovery, Monitoring, and Long-term Follow-up

The time from transplant to engraftment is a key indicator of transplant success, and the days following transplant are critical for monitoring of patient outcomes. This period of monitoring continues even after engraftment and discharge, with transplanters consistently following up to mitigate complications and track progress.2,14

BARRIERS THROUGHOUT THE JOURNEY PREVENT PATIENTS FROM EVEN BEING CONSIDERED AND PROCEEDING WITH TRANSPLANT, EXCLUDING THEM FROM THIS POTENTIAL CURE.

CONTINUE TO LEARN ABOUT ADVANCEMENTS IN THE ALLO-HSCT LANDSCAPE.

SEEKING CHANGE
SEEKING CHANGE

Determination of transplant success is complex, and requires EVALUATION OF MULTIPLE PERFORMANCE INDICATORS across a period of time.

Transplant physicians and healthcare providers must manage outcomes while also seeking opportunities to increase equity in transplant.

But today, as NEW VISTAS IN CELL ENGINEERING AND TECHNOLOGY EMERGE, innovations will lead us to the next step in expectations for donor sources and transplant outcomes.

WHERE ARE NEW PROMISING ADVANCEMENTS HAPPENING
IN THE ALLO-HSCT LANDSCAPE?

EX VIVO
EXPANSION

NOVEL
HLA TYPING

OPTIMIZATION
OF CONDITIONING REGIMENS

SELECTION OF OPTIMAL DONOR SOURCE

GvHD
PROPHYLAXIS
AND TREATMENT

GRAFT ENGINEERING
AND ADOPTIVE IMMUNOTHERAPY

SUPPORTIVE
CARE

Ex vivo expansion of stem cells may help to alleviate the issue of cell shortage for transplantation purposes. Development of optimal conditions for expansion and preservation of cellular functionality and phenotype during expansion may lead to critical advancements in cellular therapy.44

CONTINUE TO SEE HOW YOU CAN JOIN THE JOURNEY.

WHERE ARE NEW PROMISING ADVANCEMENTS HAPPENING
IN THE ALLO-HSCT LANDSCAPE?

EX VIVO
EXPANSION

NOVEL
HLA TYPING

OPTIMIZATION
OF CONDITIONING REGIMENS

SELECTION OF OPTIMAL DONOR SOURCE

GvHD
PROPHYLAXIS
AND TREATMENT

GRAFT ENGINEERING
AND ADOPTIVE IMMUNOTHERAPY

SUPPORTIVE
CARE

Ex vivo expansion of stem cells may help to alleviate the issue of cell shortage for transplantation purposes. Development of optimal conditions for expansion and preservation of cellular functionality and phenotype during expansion may lead to critical advancements in cellular therapy.44

CONTINUE TO SEE HOW YOU CAN JOIN THE JOURNEY.